Abvc Biopharma (ABVC) Common Equity (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Common Equity came in at $12.8 million in Q1 2026, up 61.24% YoY from $8.0 million in Q1 2025, and up 15.45% on a QoQ basis from $11.1 million in Q4 2025.
Abvc Biopharma (ABVC) Common Equity (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 16 years of Common Equity data on file, last reported at $12.8 million in Q1 2026.
- Quarterly Common Equity rose 61.24% year-over-year to $12.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.8 million (up 61.24% YoY) and the FY2025 annual result came in at $11.1 million, up 1434.87% from the prior year.
- Common Equity grew to $12.8 million in Q1 2026, from $11.1 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $12.8 million in Q1 2026 to a low of $723959.0 in Q4 2024.
- A 5-year average of $5.6 million and a median of $5.7 million in 2022 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity soared 1679.2% — and 2024, when it plunged 85.25%.
- Tracing ABVC's Common Equity over 5 years: stood at $1.4 million in 2022, then declined by 7.45% to $1.3 million in 2023, then slumped by 42.24% to $723959.0 in 2024, then soared by 1434.87% to $11.1 million in 2025, then grew by 15.45% to $12.8 million in 2026.
- The last three Common Equity figures came in at $12.8 million (Q1 2026), $11.1 million (Q4 2025), and $12.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 9.79 Bn |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | 12.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.27 Mn |
| Mar 31, 2026 | 12.83 Mn |
| Dec 31, 2025 | 11.11 Mn |
| Sep 30, 2025 | 12.06 Mn |
| Jun 30, 2025 | 9.49 Mn |
| Mar 31, 2025 | 7.96 Mn |
| Dec 31, 2024 | 723,959.00 |
| Sep 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.54 Mn |
| Mar 31, 2024 | 1.46 Mn |
| Dec 31, 2023 | 1.25 Mn |
| Sep 30, 2023 | 9.06 Mn |
| Jun 30, 2023 | 1.36 Mn |
| Mar 31, 2023 | 1.73 Mn |
| Dec 31, 2022 | 1.35 Mn |
| Sep 30, 2022 | 5.69 Mn |
| Jun 30, 2022 | 9.18 Mn |
| Mar 31, 2022 | 7.36 Mn |
| Dec 31, 2021 | 8.87 Mn |
| Sep 30, 2021 | 7.59 Mn |